SARS-CoV-2 Gamma and Delta Variants of Concern Might Undermine Neutralizing Activity Generated in Response to BNT162b2 mRNA Vaccination
The Delta variant raised concern regarding its ability to evade SARS-CoV-2 vaccines. We evaluated a serum neutralizing response of 172 Italian healthcare workers, three months after complete Comirnaty (BNT162b2 mRNA, BioNTech-Pfizer) vaccination, testing their sera against viral isolates of Alpha, G...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-04-01
|
| Series: | Viruses |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4915/14/4/814 |
| _version_ | 1827599079761248256 |
|---|---|
| author | Luigia Trabace Lorenzo Pace Maria Grazia Morgese Isabel Bianca Santo Domenico Galante Stefania Schiavone Dora Cipolletta Anna Maria Rosa Pierluigi Reveglia Antonio Parisi Paolo Tucci Giovanni Pepe Rodolfo Sacco Maria Pia Foschino Barbaro Gaetano Corso Antonio Fasanella |
| author_facet | Luigia Trabace Lorenzo Pace Maria Grazia Morgese Isabel Bianca Santo Domenico Galante Stefania Schiavone Dora Cipolletta Anna Maria Rosa Pierluigi Reveglia Antonio Parisi Paolo Tucci Giovanni Pepe Rodolfo Sacco Maria Pia Foschino Barbaro Gaetano Corso Antonio Fasanella |
| author_sort | Luigia Trabace |
| collection | DOAJ |
| description | The Delta variant raised concern regarding its ability to evade SARS-CoV-2 vaccines. We evaluated a serum neutralizing response of 172 Italian healthcare workers, three months after complete Comirnaty (BNT162b2 mRNA, BioNTech-Pfizer) vaccination, testing their sera against viral isolates of Alpha, Gamma and Delta variants, including 36 subjects with a previous SARS-CoV-2 infection. We assessed whether IgG anti-spike TRIM levels and serum neutralizing activity by seroneutralization assay were associated. Concerning Gamma variant, a two-fold reduction in neutralizing titres compared to the Alpha variant was observed, while a four-fold reduction of Delta virus compared to Alpha was found. A gender difference was observed in neutralizing titres only for the Gamma variant. The serum samples of 36 previously infected SARS-CoV-2 individuals neutralized Alpha, Gamma and Delta variants, demonstrating respectively a nearly three-fold and a five-fold reduction in neutralizing titres compared to Alpha variant. IgG anti-spike TRIM levels were positively correlated with serum neutralizing titres against the three variants. The Comirnaty vaccine provides sustained neutralizing antibody activity towards the Alpha variant, but it is less effective against Gamma and even less against Delta variants. |
| first_indexed | 2024-03-09T04:07:31Z |
| format | Article |
| id | doaj.art-2c2902f62697492db0eddbedd6cecc80 |
| institution | Directory Open Access Journal |
| issn | 1999-4915 |
| language | English |
| last_indexed | 2024-03-09T04:07:31Z |
| publishDate | 2022-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Viruses |
| spelling | doaj.art-2c2902f62697492db0eddbedd6cecc802023-12-03T14:04:37ZengMDPI AGViruses1999-49152022-04-0114481410.3390/v14040814SARS-CoV-2 Gamma and Delta Variants of Concern Might Undermine Neutralizing Activity Generated in Response to BNT162b2 mRNA VaccinationLuigia Trabace0Lorenzo Pace1Maria Grazia Morgese2Isabel Bianca Santo3Domenico Galante4Stefania Schiavone5Dora Cipolletta6Anna Maria Rosa7Pierluigi Reveglia8Antonio Parisi9Paolo Tucci10Giovanni Pepe11Rodolfo Sacco12Maria Pia Foschino Barbaro13Gaetano Corso14Antonio Fasanella15Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, ItalyIstituto Zooprofilattico Sperimentale della Puglia e della Basilicata, 71121 Foggia, ItalyDepartment of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, ItalyLaboratory of Clinical Pathology, Policlinico Riuniti di Foggia, 71122 Foggia, ItalyIstituto Zooprofilattico Sperimentale della Puglia e della Basilicata, 71121 Foggia, ItalyDepartment of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, ItalyIstituto Zooprofilattico Sperimentale della Puglia e della Basilicata, 71121 Foggia, ItalyLaboratory of Clinical Pathology, Policlinico Riuniti di Foggia, 71122 Foggia, ItalyDepartment of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, ItalyIstituto Zooprofilattico Sperimentale della Puglia e della Basilicata, 71121 Foggia, ItalyDepartment of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, ItalyCentro Antiveleni, Policlinico Riuniti di Foggia, 71122 Foggia, ItalyGastroenterology Unit, Department of Medical Sciences, Policlinico Riuniti di Foggia, 71122 Foggia, ItalyDepartment of Medical and Surgical Sciences, Institute of Respiratory Diseases, University of Foggia, 71122 Foggia, ItalyDepartment of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, ItalyIstituto Zooprofilattico Sperimentale della Puglia e della Basilicata, 71121 Foggia, ItalyThe Delta variant raised concern regarding its ability to evade SARS-CoV-2 vaccines. We evaluated a serum neutralizing response of 172 Italian healthcare workers, three months after complete Comirnaty (BNT162b2 mRNA, BioNTech-Pfizer) vaccination, testing their sera against viral isolates of Alpha, Gamma and Delta variants, including 36 subjects with a previous SARS-CoV-2 infection. We assessed whether IgG anti-spike TRIM levels and serum neutralizing activity by seroneutralization assay were associated. Concerning Gamma variant, a two-fold reduction in neutralizing titres compared to the Alpha variant was observed, while a four-fold reduction of Delta virus compared to Alpha was found. A gender difference was observed in neutralizing titres only for the Gamma variant. The serum samples of 36 previously infected SARS-CoV-2 individuals neutralized Alpha, Gamma and Delta variants, demonstrating respectively a nearly three-fold and a five-fold reduction in neutralizing titres compared to Alpha variant. IgG anti-spike TRIM levels were positively correlated with serum neutralizing titres against the three variants. The Comirnaty vaccine provides sustained neutralizing antibody activity towards the Alpha variant, but it is less effective against Gamma and even less against Delta variants.https://www.mdpi.com/1999-4915/14/4/814BNT162b2 mRNASARS-CoV-2 VOCsneutralizing antibodies |
| spellingShingle | Luigia Trabace Lorenzo Pace Maria Grazia Morgese Isabel Bianca Santo Domenico Galante Stefania Schiavone Dora Cipolletta Anna Maria Rosa Pierluigi Reveglia Antonio Parisi Paolo Tucci Giovanni Pepe Rodolfo Sacco Maria Pia Foschino Barbaro Gaetano Corso Antonio Fasanella SARS-CoV-2 Gamma and Delta Variants of Concern Might Undermine Neutralizing Activity Generated in Response to BNT162b2 mRNA Vaccination Viruses BNT162b2 mRNA SARS-CoV-2 VOCs neutralizing antibodies |
| title | SARS-CoV-2 Gamma and Delta Variants of Concern Might Undermine Neutralizing Activity Generated in Response to BNT162b2 mRNA Vaccination |
| title_full | SARS-CoV-2 Gamma and Delta Variants of Concern Might Undermine Neutralizing Activity Generated in Response to BNT162b2 mRNA Vaccination |
| title_fullStr | SARS-CoV-2 Gamma and Delta Variants of Concern Might Undermine Neutralizing Activity Generated in Response to BNT162b2 mRNA Vaccination |
| title_full_unstemmed | SARS-CoV-2 Gamma and Delta Variants of Concern Might Undermine Neutralizing Activity Generated in Response to BNT162b2 mRNA Vaccination |
| title_short | SARS-CoV-2 Gamma and Delta Variants of Concern Might Undermine Neutralizing Activity Generated in Response to BNT162b2 mRNA Vaccination |
| title_sort | sars cov 2 gamma and delta variants of concern might undermine neutralizing activity generated in response to bnt162b2 mrna vaccination |
| topic | BNT162b2 mRNA SARS-CoV-2 VOCs neutralizing antibodies |
| url | https://www.mdpi.com/1999-4915/14/4/814 |
| work_keys_str_mv | AT luigiatrabace sarscov2gammaanddeltavariantsofconcernmightundermineneutralizingactivitygeneratedinresponsetobnt162b2mrnavaccination AT lorenzopace sarscov2gammaanddeltavariantsofconcernmightundermineneutralizingactivitygeneratedinresponsetobnt162b2mrnavaccination AT mariagraziamorgese sarscov2gammaanddeltavariantsofconcernmightundermineneutralizingactivitygeneratedinresponsetobnt162b2mrnavaccination AT isabelbiancasanto sarscov2gammaanddeltavariantsofconcernmightundermineneutralizingactivitygeneratedinresponsetobnt162b2mrnavaccination AT domenicogalante sarscov2gammaanddeltavariantsofconcernmightundermineneutralizingactivitygeneratedinresponsetobnt162b2mrnavaccination AT stefaniaschiavone sarscov2gammaanddeltavariantsofconcernmightundermineneutralizingactivitygeneratedinresponsetobnt162b2mrnavaccination AT doracipolletta sarscov2gammaanddeltavariantsofconcernmightundermineneutralizingactivitygeneratedinresponsetobnt162b2mrnavaccination AT annamariarosa sarscov2gammaanddeltavariantsofconcernmightundermineneutralizingactivitygeneratedinresponsetobnt162b2mrnavaccination AT pierluigireveglia sarscov2gammaanddeltavariantsofconcernmightundermineneutralizingactivitygeneratedinresponsetobnt162b2mrnavaccination AT antonioparisi sarscov2gammaanddeltavariantsofconcernmightundermineneutralizingactivitygeneratedinresponsetobnt162b2mrnavaccination AT paolotucci sarscov2gammaanddeltavariantsofconcernmightundermineneutralizingactivitygeneratedinresponsetobnt162b2mrnavaccination AT giovannipepe sarscov2gammaanddeltavariantsofconcernmightundermineneutralizingactivitygeneratedinresponsetobnt162b2mrnavaccination AT rodolfosacco sarscov2gammaanddeltavariantsofconcernmightundermineneutralizingactivitygeneratedinresponsetobnt162b2mrnavaccination AT mariapiafoschinobarbaro sarscov2gammaanddeltavariantsofconcernmightundermineneutralizingactivitygeneratedinresponsetobnt162b2mrnavaccination AT gaetanocorso sarscov2gammaanddeltavariantsofconcernmightundermineneutralizingactivitygeneratedinresponsetobnt162b2mrnavaccination AT antoniofasanella sarscov2gammaanddeltavariantsofconcernmightundermineneutralizingactivitygeneratedinresponsetobnt162b2mrnavaccination |